中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1631 records (took 0.042 seconds)

    HIGH THROUGHPUT CELL MIGRATION ASSAY PLATES AND METHODS OF FABRICATION
    46.
    发明公开
    HIGH THROUGHPUT CELL MIGRATION ASSAY PLATES AND METHODS OF FABRICATION 审中-公开

    公开(公告)号：US20230398539A1

    公开(公告)日：2023-12-14

    申请号：US18249864

    申请日：2021-10-22

    Applicant: The Board of Regents of The University of Texas System

    Inventor： Robert M. BACHOO ,  Digant P. DAVÉ

    IPC: B01L3/00

    CPC classification number: B01L3/502761 ,  B01L3/502707 ,  B01L2200/12 ,  B01L2300/0829 ,  B01L2200/025 ,  B01L2300/12 ,  B01L2200/0647

    Abstract: A Cell Migration Assay Plates (CMAP) assembly for high throughput microfluidic migration assays and method of manufacturing thereof are provided. The CMAP assembly includes a top plate having a plurality of wells aligned with a bottom plate having a plurality of troughs. Each of the plurality of wells is defined at least in part by first and second reservoirs and a divisional wall extending between the reservoirs. The bottom plate is secured to the top plate to form a plurality of micro-channels, such that each one of the plurality of micro-channels is defined by a portion of one of the divisional walls and a portion of a corresponding one of the plurality of troughs. The plurality of micro-channels enable communication between the reservoirs and visualization of cells migrating through the micro-channels. In this manner, migration of cells through the micro-channels can be visualized for testing and screening applications.

    DEEP LEARNING SYSTEM FOR PREDICTING THE T CELL RECEPTOR BINDING SPECIFICITY OF NEOANTIGENS
    48.
    发明公开
    DEEP LEARNING SYSTEM FOR PREDICTING THE T CELL RECEPTOR BINDING SPECIFICITY OF NEOANTIGENS 审中-公开

    公开(公告)号：US20230349914A1

    公开(公告)日：2023-11-02

    申请号：US18029395

    申请日：2021-09-30

    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

    Inventor： Tianshi LU ,  Tao WANG

    IPC: G01N33/68 ,  G06N3/08 ,  G16B40/20 ,  G16B15/30

    CPC classification number: G01N33/6845 ,  G06N3/08 ,  G06N3/0455 ,  G16B40/20 ,  G16B15/30

    Abstract: Neoantigens play a key role in the recognition of tumor cells by T cells. However, only a small proportion of neoantigens truly elicit T cell responses, and fewer clues exist as to which neoantigens are recognized by which T cell receptors (TCRs). To help determine the TCRs that interact with particular neoantigens, prediction models that predict TCR-binding specificities of neoantigens presented by different classes of major histocompatibility complex (MHCs) were developed. To confirm the applicability of the model to clinical settings, the prediction models were comprehensively validated by a series of analyses. The validated prediction models used a flexible transfer learning approach and differential learning schema to achieve highly accurate prediction of TCR binding specificity only using TCR sequence data, antigen sequence data, and MHC alleles.

    DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS
    49.
    发明公开
    DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS 审中-公开

    公开(公告)号：US20230338485A1

    公开(公告)日：2023-10-26

    申请号：US18027993

    申请日：2021-09-23

    Applicant: UNIVERSITY OF HOUSTON SYSTEM ,  BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

    Inventor： Preethi Gunaratne ,  Brandon Mistretta ,  Sakuni Rankothgedera ,  Micah Castillo ,  Isabelle Bedrosian

    IPC: A61K39/00 ,  A61P35/00

    CPC classification number: A61K39/0011 ,  A61P35/00 ,  A61K2039/53

    Abstract: Embodiments of the present disclosure pertain to methods of treating or preventing a cancer in a subject by administering to the subject an immunogenic peptide and/or a nucleotide sequence that expresses the immunogenic peptide. Thereafter, the administered or expressed immunogenic peptide elicits an immune response against cells associated with the cancer. The immunogenic peptides contain a neoantigenic region and are expressed by chimeric nucleotide sequences derived from cells associated with the cancer. The chimeric nucleotide sequences have a higher prevalence in cancer cells when compared to non-cancer cells. Further embodiments pertain to compositions that include the immunogenic peptides of the present disclosure and/or a nucleotide sequences that express them. Additional embodiments pertain to methods of identifying immunogenic peptides by screening cells associated with a cancer for one or more chimeric nucleotide sequences; identifying peptides expressed by the chimeric nucleotide sequences; and selecting immunogenic peptides from the identified peptides.

Patent Agency Ranking